Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Agkistrodon acutus venom thrombin-like enzymes (TLEs) and antithrombin factors represent a complex group of proteins found in the venom of the sharp-nosed pit viper, a medically significant snake in East Asia [4]. TLEs, such as acutin and acutobin, are serine proteases that functionally mimic human thrombin by cleaving fibrinogen into fibrin; however, they typically do not activate Factor XIII, resulting in the formation of unstable, easily degraded fibrin polymers and subsequent systemic defibrinogenation [1][2]. Antithrombin factors, often belonging to the C-type lectin-like protein family, further disrupt hemostasis by directly binding to and inhibiting thrombin or other critical coagulation factors like Factor X [3]. Clinically, these proteins are the primary targets for neutralization by specific antivenoms during the management of snakebite envenomation, which is characterized by severe coagulopathy and hemorrhage [4]. Beyond their toxicological role, purified TLEs from this species have been investigated as therapeutic defibrinogenating agents for treating thrombotic disorders, such as ischemic stroke, by reducing blood viscosity and preventing further clot growth [2]. Monitoring the activity of these components in patients involves measuring coagulation parameters like plasma fibrinogen levels and prothrombin time.
Thrombin-like enzymes (TLEs) catalyze the release of fibrinopeptides from fibrinogen to form unstable fibrin clots, leading to consumptive defibrinogenation [1][2]. Antithrombin factors bind to and inhibit the activity of thrombin or other coagulation factors, preventing the conversion of fibrinogen to fibrin [3].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Agkistrodon acutus venom thrombin-like enzymes and antithrombin factors (AaV-TLE/AF).